News
Stay up to date on topics that are important to Nurse Practitioners.
-
CDC: STDs Continued to Increase During First Year of COVID-19 Pandemic
The US Centers for Disease Control and Prevention (CDC) announced that sexually transmitted diseases (STDs) continued to increase…
-
FDA Approves First Sublingual Medication for Agitation in Serious Mental Illness
The FDA approved dexmedetomidine (Igalmi) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar…
-
New York and Kansas Grant Full Practice Authority to NPs
Nurse practitioners licensed in New York and Kansas are now fully able to practice independently, joining 24 other…
-
Appropriate Antibiotic Prescribing for Acute Respiratory Infections
In 2020, healthcare providers prescribed 201.9 million antibiotic prescriptions—equivalent to 613 antibiotic prescriptions per 1,000 persons.1 Studies have…
-
FDA Approves New Indication for IL-23 Inhibitor for Adults With Active Psoriatic Arthritis
Risankizumab-rzaa (Skyrizi) is now approved for the treatment of adults with active psoriatic arthritis. It is the only…
-
Carbidopa/Levodopa Fractional Tablet Now Available for Parkinson’s Disease
A carbidopa/levodopa tablet formulation (Dhivy) designed to facilitate dose adjustment is now available for the treatment of Parkinson’s…
-
FDA Approves Treatment for Wider Range of Patients With Heart Failure
The FDA approved empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure in…
-
New Migraine Treatment Approved in Adults
Celecoxib oral solution (Elyxyb) was approved for the acute treatment of migraine with or without aura in adults.…
-
CDC Advises Moderately or Severely Immunocompromised Teens, Adults to Get Fourth COVID-19 Shot
The Centers for Disease Control and Prevention (CDC) advised that moderately or severely immunocompromised teens and adults receive…
-
New-Onset Bladder Symptoms in Discharged COVID Patients
Men and women who have been hospitalized with COVID-19 have reported new-onset severe genitourinary symptoms, including increased frequency,…
-
FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to Omicron Variant
The FDA revised the authorization for two monoclonal antibody treatments, bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab…
-
FDA Approves Remdesivir (Veklury) for Outpatient COVID-19 Treatment
The FDA has expanded the approved use of remdesivir (Veklury) to certain non-hospitalized adults and pediatric patients for…
Trending
-
FDA Approved Semaglutide Injection to Reduce Risk of Serious Heart Problems in Overweight Adults
-
The Role of Pharmacogenomics in Precision Mental Healthcare
-
What Questions Should I Ask at the End of My NP Job Interview?
-
Navigating Substance Use Disorder as an NP: Screening, Treatment, and Education
-
Pharmacology Spotlight: Understanding Pharmacokinetics & Pharmacodynamics
-
Suicide Prevention Training for Mental Health Nurse Practitioners
-
Why Continuing Education is Essential for NP Career Advancement
-
Beyond Prescriptions: 6 Tips for a Holistic FNP Approach to Psychopharmacology
-
How to Set Boundaries to Avoid NP Burnout
-
Using Technology to Combat Drug-Drug Interactions
-
Ten Key Tips for Balancing School, Work, and Life as an NP Student
-
Top 5 Lab Test Result Interpretation Mistakes (and How to Avoid Them)
Join our email list
Get new course alerts, newsletters and more delivered directly to your inbox
By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.